Cargando…
The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China
BACKGROUND: Data on outcomes following transcatheter aortic valve replacement with SAPIEN 3 in China is limited as it was approved by the National Medical Products since 2020. The present study was designed to collect clinical data on the SAPIEN 3 aortic valve in Chinese patients with bicuspid aorti...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293831/ https://www.ncbi.nlm.nih.gov/pubmed/37383702 http://dx.doi.org/10.3389/fcvm.2023.1064255 |
_version_ | 1785063072457555968 |
---|---|
author | Shang, Xiaoke Pan, Xiangbin Zhang, Gejun Jiang, Zhengming Liu, Xianbao Song, Guangyuan Li, Yi Wang, Yan Luo, Jianfang Tang, Yida Yuan, Yiqiang Wu, Yongjian Ma, Xiang Zhu, Dan Zhong, Yucheng Zhang, Changdong Dong, Nianguo |
author_facet | Shang, Xiaoke Pan, Xiangbin Zhang, Gejun Jiang, Zhengming Liu, Xianbao Song, Guangyuan Li, Yi Wang, Yan Luo, Jianfang Tang, Yida Yuan, Yiqiang Wu, Yongjian Ma, Xiang Zhu, Dan Zhong, Yucheng Zhang, Changdong Dong, Nianguo |
author_sort | Shang, Xiaoke |
collection | PubMed |
description | BACKGROUND: Data on outcomes following transcatheter aortic valve replacement with SAPIEN 3 in China is limited as it was approved by the National Medical Products since 2020. The present study was designed to collect clinical data on the SAPIEN 3 aortic valve in Chinese patients with bicuspid aortic valve and tricuspid aortic valve stenosis. METHODS: We analyzed the patient characteristics, procedural features and procedural outcomes of the first 438 patients (223 for bicuspid aortic valve and 215 tricuspid aortic valve) from 21 provinces in 74 sites treated with the SAPIEN 3 valve system for transcatheter aortic valve replacement between September 2020 and May 2022. RESULTS: Procedural mortality was 0.7%. 5 cases during the operation were converted to surgery. Among 438 cases, permanent pacemaker implantation was performed in a total of 12 cases (2.7%). The patient had severe leaflet calcification of the aortic valve, with moderate and severe calcification reaching 39.7% and 35.2% respectively. The size of the implanted valves was predominantly 26 mm and 23 mm, reaching 42.5% and 39.5% respectively. The incidence of moderate or severe perivalvular leak in the postoperative period was 0.5%, with a predominance of 90/10 and 80/20 valve deployment height. There was a significant difference in the deployment height of the valve between bicuspid aortic valve and tricuspid aortic valve, with the bicuspid aortic valve having a more deployment height of 90/10. Annulus size in bicuspid aortic valve group was significantly larger than tricuspid aortic valve group. Valve sizing for oversized, within size, and undersized were different between bicuspid aortic valve and tricuspid aortic valve. CONCLUSIONS: Procedural success rates were high, with similar and good results for bicuspid aortic valve and tricuspid aortic valve, low perivalvular leak for both valve types, and low permanent pacemaker implantation rates for both valve types. Annulus size, valve sizing and coronary artery height were significantly different in the BAV and TAV group. |
format | Online Article Text |
id | pubmed-10293831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102938312023-06-28 The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China Shang, Xiaoke Pan, Xiangbin Zhang, Gejun Jiang, Zhengming Liu, Xianbao Song, Guangyuan Li, Yi Wang, Yan Luo, Jianfang Tang, Yida Yuan, Yiqiang Wu, Yongjian Ma, Xiang Zhu, Dan Zhong, Yucheng Zhang, Changdong Dong, Nianguo Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Data on outcomes following transcatheter aortic valve replacement with SAPIEN 3 in China is limited as it was approved by the National Medical Products since 2020. The present study was designed to collect clinical data on the SAPIEN 3 aortic valve in Chinese patients with bicuspid aortic valve and tricuspid aortic valve stenosis. METHODS: We analyzed the patient characteristics, procedural features and procedural outcomes of the first 438 patients (223 for bicuspid aortic valve and 215 tricuspid aortic valve) from 21 provinces in 74 sites treated with the SAPIEN 3 valve system for transcatheter aortic valve replacement between September 2020 and May 2022. RESULTS: Procedural mortality was 0.7%. 5 cases during the operation were converted to surgery. Among 438 cases, permanent pacemaker implantation was performed in a total of 12 cases (2.7%). The patient had severe leaflet calcification of the aortic valve, with moderate and severe calcification reaching 39.7% and 35.2% respectively. The size of the implanted valves was predominantly 26 mm and 23 mm, reaching 42.5% and 39.5% respectively. The incidence of moderate or severe perivalvular leak in the postoperative period was 0.5%, with a predominance of 90/10 and 80/20 valve deployment height. There was a significant difference in the deployment height of the valve between bicuspid aortic valve and tricuspid aortic valve, with the bicuspid aortic valve having a more deployment height of 90/10. Annulus size in bicuspid aortic valve group was significantly larger than tricuspid aortic valve group. Valve sizing for oversized, within size, and undersized were different between bicuspid aortic valve and tricuspid aortic valve. CONCLUSIONS: Procedural success rates were high, with similar and good results for bicuspid aortic valve and tricuspid aortic valve, low perivalvular leak for both valve types, and low permanent pacemaker implantation rates for both valve types. Annulus size, valve sizing and coronary artery height were significantly different in the BAV and TAV group. Frontiers Media S.A. 2023-06-13 /pmc/articles/PMC10293831/ /pubmed/37383702 http://dx.doi.org/10.3389/fcvm.2023.1064255 Text en © 2023 Shang, Pan, Zhang, Jiang, Liu, Song, Li, Wang, Luo, Tang, Yuan, Wu, Ma, Zhu, Zhong, Zhang and Dong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Shang, Xiaoke Pan, Xiangbin Zhang, Gejun Jiang, Zhengming Liu, Xianbao Song, Guangyuan Li, Yi Wang, Yan Luo, Jianfang Tang, Yida Yuan, Yiqiang Wu, Yongjian Ma, Xiang Zhu, Dan Zhong, Yucheng Zhang, Changdong Dong, Nianguo The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China |
title | The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China |
title_full | The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China |
title_fullStr | The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China |
title_full_unstemmed | The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China |
title_short | The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China |
title_sort | first clinical data of the sapien 3 aortic valve in the treatment of aortic stenosis in china |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293831/ https://www.ncbi.nlm.nih.gov/pubmed/37383702 http://dx.doi.org/10.3389/fcvm.2023.1064255 |
work_keys_str_mv | AT shangxiaoke thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT panxiangbin thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT zhanggejun thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT jiangzhengming thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT liuxianbao thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT songguangyuan thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT liyi thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT wangyan thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT luojianfang thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT tangyida thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT yuanyiqiang thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT wuyongjian thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT maxiang thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT zhudan thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT zhongyucheng thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT zhangchangdong thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT dongnianguo thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT shangxiaoke firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT panxiangbin firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT zhanggejun firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT jiangzhengming firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT liuxianbao firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT songguangyuan firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT liyi firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT wangyan firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT luojianfang firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT tangyida firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT yuanyiqiang firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT wuyongjian firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT maxiang firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT zhudan firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT zhongyucheng firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT zhangchangdong firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina AT dongnianguo firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina |